UPDATE: Morgan Stanley Raising Price Target On Alexion Pharmaceuticals

Morgan Stanley is out with a research report on Alexion Pharmaceuticals ALXN and is raising its price target to $61 from $56 after it reported earnings. It has an Overweight rating on shares. In a note to clients, Morgan Stanley writes, "Alexion reported a strong 2Q11 with Soliris sales of $185.7mn ahead of both our and the Street's expectation of $178mn. In addition, the company raised revenue guidance meaningfully (from $720-$740mn to $745-$755mn) for 2011 sales. We continue to expect solid Soliris growth in the remainder of 2011 and beyond as 1) the base PNH business continues to grow in the existing US/EU markets, 2) the more recent launches in Japan and Australia accelerate, and 3) a HUS approval in the US is likely before YE11." Shares of ALXN gained $4/73 yesterday to close at $56.77, a gain of 9.09%.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyHealth CareMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!